{"title_page": "AMG-3", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 477346872\n| IUPAC_name = (6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol\n| image = AMG-3.png\n| width = 240\n\n<!--Clinical data-->\n| tradename =  \n| legal_status =  \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 179044-94-1 \n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = U90K6D923K \n| ChEMBL_Ref = {{ebicite|changed|EBI}}\n| ChEMBL = 476325\n| PubChem = 10002952\n|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = 8178532\n|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C25H36O2S2/c1-5-6-7-8-11-25(28-12-13-29-25)18-15-21(26)23-19-14-17(2)9-10-20(19)24(3,4)27-22(23)16-18/h9,15-16,19-20,26H,5-8,10-14H2,1-4H3/t19-,20-/m1/s1\n|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = JECXXFXYJAQVAH-WOJBJXKFSA-N\n\n<!--Chemical data-->\n| C=25 | H=36 | O=2 | S=2 \n| molecular_weight = 432.681 g/mol\n| smiles = CCCCCCC4(SCCS4)c(cc1O)cc(OC(C)(C)C2CC=3)c1C2CC=3C\n}}\n\n'''AMG-3''' (part of the [[List of AM cannabinoids|AM cannabinoid series]]) is an [[analgesic]] drug which is a [[cannabinoid]] [[agonist]]. It is a derivative of \u03948[[THC]] substituted with a [[dithiolane]] group on the 3-position side chain.<ref>{{cite journal | vauthors = Mavromoustakos T, Theodoropoulou E, Zervou M, Kourouli T, Papahatjis D | title = Structure elucidation and conformational properties of synthetic cannabinoids (-)-2-(6a,7,10,10a-tetrahydro-6,6,9-trimethyl-1-hydroxy-6H-dibe nzo [b,d]pyranyl)-2-hexyl-1,3-dithiolane and its methylated analog | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 18 | issue = 6 | pages = 947\u201356 | date = January 1999 | pmid = 9925329 | doi = 10.1016/s0731-7085(98)00100-9 }}</ref> AMG-3 is a potent agonist at both [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] [[Receptor (biochemistry)|receptors]] with a [[Dissociation constant|K<sub>i</sub>]] of 0.32nM at CB<sub>1</sub> and 0.52nM at CB<sub>2</sub>,<ref>{{cite journal | vauthors = Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A | title = Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 7 | pages = 1195\u2013200 | date = March 1998 | pmid = 9544219 | doi = 10.1021/jm970277i }}</ref><ref>{{cite journal | vauthors = Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, Makriyannis A | title = Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1' | journal = Journal of Medicinal Chemistry | volume = 46 | issue = 15 | pages = 3221\u20139 | date = July 2003 | pmid = 12852753 | doi = 10.1021/jm020558c }}</ref> and its particularly high binding affinity has led to it being used as a template for further structural development of novel cannabinoid drugs.<ref>{{cite journal | vauthors = Durdagi S, Papadopoulos MG, Papahatjis DP, Mavromoustakos T | title = Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 17 | issue = 24 | pages = 6754\u201363 | date = December 2007 | pmid = 17980589 | doi = 10.1016/j.bmcl.2007.10.044 }}</ref> It has [[sedative]] and analgesic effects, with analgesia lasting for up to 36 hours after administration.<ref>{{cite journal | vauthors = Antoniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraki C | display-authors = 6 | title = Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3 | journal = Behavioural Pharmacology | volume = 16 | issue = 5-6 | pages = 499\u2013510 | date = September 2005 | pmid = 16148456 }}</ref>\n\n== See also ==\n* [[AMG-36]]\n* [[AMG-41]]\n\n== References ==\n{{reflist}}\n\n{{cannabinoids}}\n\n[[Category:Cannabinoids]]\n[[Category:Benzochromenes]]\n[[Category:Phenols]]\n[[Category:Dithiolanes]]\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| Watchedfields = changed\n| verifiedrevid = 477346872\n| IUPAC_name = (6aR,10aR)-3-(2-hexyl-1,3-dithiolan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol\n| image = AMG-3.png\n| width = 240\n\n<!--Clinical data-->\n| tradename =  \n| legal_status =  \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = {{cascite|changed|??}}\n| CAS_number = 179044-94-1  \n| ChEMBL_Ref = {{ebicite|changed|EBI}}\n| ChEMBL = 476325\n| PubChem = 10002952\n|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = 8178532\n|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C25H36O2S2/c1-5-6-7-8-11-25(28-12-13-29-25)18-15-21(26)23-19-14-17(2)9-10-20(19)24(3,4)27-22(23)16-18/h9,15-16,19-20,26H,5-8,10-14H2,1-4H3/t19-,20-/m1/s1\n|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = JECXXFXYJAQVAH-WOJBJXKFSA-N\n\n<!--Chemical data-->\n| C=25 | H=36 | O=2 | S=2 \n| molecular_weight = 432.681 g/mol\n| smiles = CCCCCCC4(SCCS4)c(cc1O)cc(OC(C)(C)C2CC=3)c1C2CC=3C\n}}\n\n'''AMG-3''' (part of the [[List of AM cannabinoids|AM cannabinoid series]]) is an [[analgesic]] drug which is a [[cannabinoid]] [[agonist]]. It is a derivative of \u03948[[THC]] substituted with a [[dithiolane]] group on the 3-position side chain.<ref>{{cite journal | vauthors = Mavromoustakos T, Theodoropoulou E, Zervou M, Kourouli T, Papahatjis D | title = Structure elucidation and conformational properties of synthetic cannabinoids (-)-2-(6a,7,10,10a-tetrahydro-6,6,9-trimethyl-1-hydroxy-6H-dibe nzo [b,d]pyranyl)-2-hexyl-1,3-dithiolane and its methylated analog | journal = Journal of Pharmaceutical and Biomedical Analysis | volume = 18 | issue = 6 | pages = 947\u201356 | date = January 1999 | pmid = 9925329 | doi = 10.1016/s0731-7085(98)00100-9 }}</ref> AMG-3 is a potent agonist at both [[Cannabinoid receptor 1|CB<sub>1</sub>]] and [[Cannabinoid receptor 2|CB<sub>2</sub>]] [[Receptor (biochemistry)|receptors]] with a [[Dissociation constant|K<sub>i</sub>]] of 0.32nM at CB<sub>1</sub> and 0.52nM at CB<sub>2</sub>,<ref>{{cite journal | vauthors = Papahatjis DP, Kourouli T, Abadji V, Goutopoulos A, Makriyannis A | title = Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 7 | pages = 1195\u2013200 | date = March 1998 | pmid = 9544219 | doi = 10.1021/jm970277i }}</ref><ref>{{cite journal | vauthors = Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, Pertwee RG, Makriyannis A | title = Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1' | journal = Journal of Medicinal Chemistry | volume = 46 | issue = 15 | pages = 3221\u20139 | date = July 2003 | pmid = 12852753 | doi = 10.1021/jm020558c }}</ref> and its particularly high binding affinity has led to it being used as a template for further structural development of novel cannabinoid drugs.<ref>{{cite journal | vauthors = Durdagi S, Papadopoulos MG, Papahatjis DP, Mavromoustakos T | title = Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 17 | issue = 24 | pages = 6754\u201363 | date = December 2007 | pmid = 17980589 | doi = 10.1016/j.bmcl.2007.10.044 }}</ref> It has [[sedative]] and analgesic effects, with analgesia lasting for up to 36 hours after administration.<ref>{{cite journal | vauthors = Antoniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraki C | display-authors = 6 | title = Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3 | journal = Behavioural Pharmacology | volume = 16 | issue = 5-6 | pages = 499\u2013510 | date = September 2005 | pmid = 16148456 }}</ref>\n\n== See also ==\n* [[AMG-36]]\n* [[AMG-41]]\n\n== References ==\n{{reflist}}\n\n{{cannabinoids}}\n\n[[Category:Cannabinoids]]\n[[Category:Benzochromenes]]\n[[Category:Phenols]]\n[[Category:Dithiolanes]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/AMG-3"}
